Cargando…

Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans

Multiple preventive vaccines are being developed to counter the coronavirus disease 2019 pandemic. The leading candidates have now been evaluated in nonhuman primates (NHPs) and human phase 1 and/or phase 2 clinical trials. Several vaccines have already advanced into phase 3 efficacy trials, while o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klasse, P. J., Nixon, Douglas F., Moore, John P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978427/ https://www.ncbi.nlm.nih.gov/pubmed/33608249 http://dx.doi.org/10.1126/sciadv.abe8065

Ejemplares similares

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
por: Corbett, Kizzmekia S., et al.
Publicado: (2020)

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine
por: Peng, Kah-Whye, et al.
Publicado: (2022)

Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates
por: Awasthi, Mayanka, et al.
Publicado: (2023)

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
por: Jones, Bryan E., et al.
Publicado: (2021)

Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates
por: Erasmus, Jesse H., et al.
Publicado: (2020)

Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines
por: Klasse, Per Johan, et al.
Publicado: (2012)

mRNA-1273 Protects against SARS-CoV-2 Beta Infection in Nonhuman Primates
por: Corbett, Kizzmekia S., et al.
Publicado: (2021)

Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization
por: Klasse, PJ, et al.
Publicado: (2020)

Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
por: Francica, Joseph R., et al.
Publicado: (2021)

The dynamics of γδ T cell responses in nonhuman primates during SARS-CoV-2 infection
por: Fears, Alyssa C., et al.
Publicado: (2022)

mRNA-1273 vaccination protects against SARS-CoV-2–elicited lung inflammation in nonhuman primates
por: Waickman, Adam T., et al.
Publicado: (2022)

Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates
por: Rossi, Shannan L, et al.
Publicado: (2019)

Nonhuman Primate Models for SARS
por: Haagmans, Bart L, et al.
Publicado: (2006)

Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection
por: Vermillion, Meghan S., et al.
Publicado: (2021)

Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2
por: Tioni, Mariana F., et al.
Publicado: (2022)

Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice
por: Sun, Shihui, et al.
Publicado: (2021)

The Gastrointestinal Tract Is an Alternative Route for SARS-CoV-2 Infection in a Nonhuman Primate Model
por: Jiao, Li, et al.
Publicado: (2021)

SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota
por: Sokol, Harry, et al.
Publicado: (2021)

An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates
por: Erasmus, Jesse H., et al.
Publicado: (2020)

Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates
por: Mukhopadhyay, Labanya, et al.
Publicado: (2021)

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M(™) vaccination
por: Gorman, Matthew J, et al.
Publicado: (2021)

Are Nonhuman Primates Good Models for SARS?
por: Hogan, Robert J
Publicado: (2006)

Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates
por: Seo, Yong Bok, et al.
Publicado: (2021)

A Case Study to Dissect Immunity to SARS-CoV-2 in a Neonate Nonhuman Primate Model
por: Fovet, Claire-Maëlle, et al.
Publicado: (2022)

Cerebrospinal Fluid Protein Markers Indicate Neuro-Damage in SARS-CoV-2-Infected Nonhuman Primates
por: Maity, Sudipa, et al.
Publicado: (2023)

Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
por: Zhu, Daniel Y., et al.
Publicado: (2022)

Analysis of R848 as an Adjuvant to Improve Inactivated Influenza Vaccine Immunogenicity in Elderly Nonhuman Primates
por: Crofts, Kali F., et al.
Publicado: (2022)

The Use of Nonhuman Primate Models in HIV Vaccine Development
por: Morgan, Cecilia, et al.
Publicado: (2008)

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
por: Francica, Joseph R., et al.
Publicado: (2021)

Immunogenicity and Protective Efficacy of a Live Attenuated H5N1 Vaccine in Nonhuman Primates
por: Fan, Shufang, et al.
Publicado: (2009)

Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates
por: Walters, Jewell N., et al.
Publicado: (2022)

Immunization with a Prefusion SARS-CoV-2 Spike Protein Vaccine (RBMRNA-176) Protects against Viral Challenge in Mice and Nonhuman Primates
por: Ma, Qinhai, et al.
Publicado: (2022)

Aging in nonhuman primates /
Publicado: (1979)

Behavior of Nonhuman Primates
por: Southwick, Charles H.
Publicado: (1966)

Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 progression
por: Zheng, Huiwen, et al.
Publicado: (2020)

Induction of Gut Microbial Tryptamine by SARS-CoV-2 in Nonhuman Primate Model Consistent with Tryptamine-Induced Model of Neurodegeneration
por: Paley, Elena L.
Publicado: (2021)

A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates
por: Stone, V. M., et al.
Publicado: (2020)

RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
por: Pan, Xiaoyan, et al.
Publicado: (2021)

Letter to the Editor: Prior Infection with Coccidioidomycosis in Nonhuman Primates and Impact on Simian Immunodeficiency Virus Disease and Vaccine Immunogenicity
por: Fuller, Deborah H., et al.
Publicado: (2022)

Comparison of Dose–Response Relationships for Two Isolates of SARS-CoV-2 in a Nonhuman Primate Model of Inhalational COVID-19
por: Dabisch, Paul A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c0esto1hc89ggje8ncic6he4j7